Zobrazeno 1 - 10
of 649
pro vyhledávání: '"Jeffrey H. Lipton"'
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1246-1252 (2024)
Severe aplastic anemia (SAA) is a life-threatening type of aplastic anemia for which allogeneic stem cell transplantation or immunosuppressive therapy are the principal treatment modalities. Only about 25–30% of patients have a matched sibling dono
Externí odkaz:
https://doaj.org/article/7fd155e966c642559c23ed08b7ffcdfd
Autor:
Jeffrey H. Lipton
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-3 (2023)
Externí odkaz:
https://doaj.org/article/c7516de9eb924752bc7a0efb5effd03b
Autor:
Jayastu Senapati, Koji Sasaki, Ghayas C. Issa, Jeffrey H. Lipton, Jerald P. Radich, Elias Jabbour, Hagop M. Kantarjian
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-12 (2023)
Abstract With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic p
Externí odkaz:
https://doaj.org/article/f3199252ca5c405e9dd66942feadd154
Autor:
Jorge Cortes, Michael Deininger, Elza Lomaia, Beatriz Moiraghi, Soledad Undurraga, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, James Mccloskey, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Christine Rojas, Anna Turkina, Moshe Talpaz, Michael Mauro, Vickie Lu, Alexander Vorog, Jane Apperley
Publikováno v:
HemaSphere, Vol 7, p e85501cf (2023)
Externí odkaz:
https://doaj.org/article/f0b8d7a160ec4ce1b84d936813ace846
Autor:
Hyeok-Jae Jang, Young-Min Woo, Kazuhito Naka, Jong-Ho Park, Ho-Jae Han, Hee-Jin Kim, Sun-Hee Kim, Jae-Sook Ahn, Taehyung Kim, Shinya Kimura, Sarah Zarabi, Jeffrey H. Lipton, Mark D. Minden, Chul-Won Jung, Hyeoung-Joon Kim, Jong-Won Kim, Dennis Dong Hwan Kim
Publikováno v:
Cancers, Vol 13, Iss 21, p 5543 (2021)
Previous studies have suggested that statins can be repurposed for cancer treatment. However, the therapeutic efficacy of statins in chronic myeloid leukemia (CML) has not yet been demonstrated. In this study, we retrospectively evaluated the outcome
Externí odkaz:
https://doaj.org/article/8322a5e3f83e40388263140905c6e5f5
Autor:
Simon Kavanagh, Jeffrey H. Lipton
Publikováno v:
European Medical Journal, Vol 2, Iss 3, Pp 15-20 (2017)
Hypereosinophilic syndromes are a group of disorders characterised by significant eosinophilia and organ damage. They have proven challenging to define, diagnose, and study for many years, due in part to their variable clinical presentations, the ove
Externí odkaz:
https://doaj.org/article/58bba5305a6140369cb80713187894ec
Autor:
Nicolas Waespe, Santhosh Dhanraj, Manju Wahala, Elena Tsangaris, Tom Enbar, Bozana Zlateska, Hongbing Li, Robert J. Klaassen, Conrad V. Fernandez, Geoff D. E. Cuvelier, John K. Wu, Yves D. Pastore, Mariana Silva, Jeffrey H. Lipton, Joseé Brossard, Bruno Michon, Sharon Abish, MacGregor Steele, Roona Sinha, Mark J. Belletrutti, Vicky R. Breakey, Lawrence Jardine, Lisa Goodyear, Liat Kofler, Michaela Cada, Lillian Sung, Mary Shago, Stephen W. Scherer, Yigal Dror
Publikováno v:
npj Genomic Medicine, Vol 2, Iss 1, Pp 1-8 (2017)
Blood disorders: impact of genomic structural variation Copy number variation in patients with inherited bone marrow failure syndromes (IBMFSs) is associated with more severe clinical symptoms. In addition to persistently low levels of red blood cell
Externí odkaz:
https://doaj.org/article/fab055366f7246f79c31483ee2eaa142
Publikováno v:
Haematologica, Vol 104, Iss 3 (2019)
Externí odkaz:
https://doaj.org/article/2779593e397543e9b6f7eaeaca502ad2
Autor:
Timothy P. Hughes, Pierre Laneuville, Philippe Rousselot, David S. Snyder, Delphine Rea, Neil P. Shah, David Paar, Elisabetta Abruzzese, Andreas Hochhaus, Jeffrey H. Lipton, Jorge E. Cortes
Publikováno v:
Haematologica, Vol 104, Iss 1 (2019)
Dasatinib, a second-generation BCR-ABL1 tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, both as first-line therapy and after imatinib intolerance
Externí odkaz:
https://doaj.org/article/ec4e47fa4ec947b39d7674db85f6b7e9
Autor:
Daniel Santa Mina, Lianne B. Dolan, Jeffrey H. Lipton, Darren Au, Encarna Camacho Pérez, Alyssa Franzese, Shabbir M. H. Alibhai, Jennifer M. Jones, Eugene Chang
Publikováno v:
Journal of Clinical Medicine, Vol 9, Iss 6, p 1854 (2020)
People with cancer who undergo allogeneic hematological stem cell transplant (allo-HSCT) experience significant deconditioning that can compromise quality of life. Exercise has shown to be beneficial before or after allo-HSCT; however, little is know
Externí odkaz:
https://doaj.org/article/b047882f21964dd0a9c8cc52bd402dc1